Loss of MD1 Promotes Inflammatory and Apoptotic Atrial Remodelling in Diabetic Cardiomyopathy by Activating the TLR4/NF-κB Signalling Pathway
Pharmacology · 2023
DOI: 10.1159/000530081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, 2023. Verfasst von Tonghuan Shi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Atrial Remodeling, Diabetes Mellitus, Experimental, Diabetic Cardiomyopathies. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Introduction
Myeloid differentiation protein 1 (MD1), a negative regulator of toll-like receptor 4 (TLR4), is widely expressed in the heart. Recent studies have shown that MD1 plays an important role in cardiac remodelling. However, the effects and potential mechanisms underlying MD1-mediated atrial remodelling in diabetic cardiomyopathy (DCM) remain unclear. Therefore, this study was designed to explore the role of MD1 in DCM-related atrial remodelling.
Methods
MD1 knockout (MD1-KO) mice and wild-type (WT) littermates were injected with streptozotocin (STZ) to establish a diabetic mouse model. These mice were then used to evaluate MD1 expression and its effects on atrial remodelling in vivo.
Results
MD1 expression was significantly decreased in STZ-induced diabetic mice. The loss of MD1 aggravated atrial fibrosis, inflammation, and apoptosis in DCM mice and promoted atrial remodelling. MD1-KO diabetic mice also showed higher susceptibility to atrial fibrillation (AF) and worse cardiac function. Mechanistically, the deletion of MD1 promoted the activation of the TLR4/NF-κB signalling pathway, resulting in atrial remodelling in DCM mice via increased p65 phosphorylation.
Conclusions
The deletion of MD1 plays an important role in inflammatory and apoptotic atrial remodelling and increases susceptibility to AF in DCM mice, providing a new target for the preventive treatment of DCM-related atrial remodelling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
- Hubei Key Laboratory of Cardiology, Cardiovascular Research Institute of Wuhan University, Wuhan, China.
- Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- The Second Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, China.
- Key Laboratory of Heart Failure Prevention and Treatment of Hengyang, Hengyang, China.
Zitieren
APA
Shi, T., Wang, G., Peng, J., & Chen, M. (2023). Loss of MD1 Promotes Inflammatory and Apoptotic Atrial Remodelling in Diabetic Cardiomyopathy by Activating the TLR4/NF-κB Signalling Pathway. Pharmacology. https://doi.org/10.1159/000530081
Vancouver
Shi T, Wang G, Peng J, Chen M. Loss of MD1 Promotes Inflammatory and Apoptotic Atrial Remodelling in Diabetic Cardiomyopathy by Activating the TLR4/NF-κB Signalling Pathway. Pharmacology. 2023. doi:10.1159/000530081
BibTeX
@article{Shi2023,
author = {Shi, Tonghuan and Wang, Guangji and Peng, Jianye and Chen, Manhua},
title = {Loss of MD1 Promotes Inflammatory and Apoptotic Atrial Remodelling in Diabetic Cardiomyopathy by Activating the TLR4/NF-κB Signalling Pathway},
journal = {Pharmacology},
year = {2023},
doi = {10.1159/000530081}
}
EUVIMED